Dr. Kristi McIntyre, MD
Claim this profileTexas Oncology - Dallas Presbyterian Hospital
Studies Breast Cancer
Studies Ovarian Cancer
26 reported clinical trials
52 drugs studied
About Kristi McIntyre, MD
Education:
- Obtained MD from the University of Texas Southwestern Medical Center in 2009.
- Completed Residency in Internal Medicine at the University of Texas Southwestern Medical Center in 2012.
- Finished Fellowship in Hematology/Oncology at the University of Texas Southwestern Medical Center in 2015.
Experience:
- Practicing as a medical oncologist and hematologist at Texas Oncology - Dallas Presbyterian Hospital since 2015.
Area of expertise
1Breast Cancer
Stage IV
Stage III
HER2 negative
2Ovarian Cancer
Stage IV
BRCA positive
FRα positive
Affiliated Hospitals
Clinical Trials Kristi McIntyre, MD is currently running
ACR-368
for Ovarian Cancer
This trial tests a new drug, ACR-368, alone or with a small dose of another drug, gemcitabine, in patients whose cancers don't respond to standard treatments. A special test helps decide which treatment might work best for each patient. Gemcitabine has been used with other drugs for various cancers, including pancreatic, lung, ovarian, and breast cancers.
Recruiting1 award Phase 210 criteria
Genomic Testing
for Breast Cancer
The FLEX Registry will be implemented to operate as a large-scale, population based, prospective registry. All patients with stage I to III breast cancer who receive MammaPrint® and BluePrint testing on a primary breast tumor are eligible for entry into the FLEX Registry, which is intended to enable additional study arms at low incremental effort and cost. FLEX Registry will utilize an adaptive design, where additional targeted substudies and arms can be added after the initial study is opened.
Recruiting1 award N/A3 criteria
More about Kristi McIntyre, MD
Clinical Trial Related4 years of experience running clinical trials · Led 26 trials as a Principal Investigator · 6 Active Clinical TrialsTreatments Kristi McIntyre, MD has experience with
- Gemcitabine
- Dexamethasone
- Mirvetuximab Soravtansine
- Rituximab
- Imlunestrant
- Abemaciclib
Breakdown of trials Kristi McIntyre, MD has run
Breast Cancer
Ovarian Cancer
Fallopian Tube Cancer
Cancer
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Kristi McIntyre, MD specialize in?
Kristi McIntyre, MD focuses on Breast Cancer and Ovarian Cancer. In particular, much of their work with Breast Cancer has involved Stage IV patients, or patients who are Stage III.
Is Kristi McIntyre, MD currently recruiting for clinical trials?
Yes, Kristi McIntyre, MD is currently recruiting for 6 clinical trials in Dallas Texas. If you're interested in participating, you should apply.
Are there any treatments that Kristi McIntyre, MD has studied deeply?
Yes, Kristi McIntyre, MD has studied treatments such as Gemcitabine, Dexamethasone, Mirvetuximab Soravtansine.
What is the best way to schedule an appointment with Kristi McIntyre, MD?
Apply for one of the trials that Kristi McIntyre, MD is conducting.
What is the office address of Kristi McIntyre, MD?
The office of Kristi McIntyre, MD is located at: Texas Oncology - Dallas Presbyterian Hospital, Dallas, Texas 75231 United States. This is the address for their practice at the Texas Oncology - Dallas Presbyterian Hospital.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.